Bioequivalence and the immunogenicity of biopharmaceuticals (original) (raw)

• Chance, R. E., Root, M. A. & Galloway, J. A. The immunogenicity of insulin preparations. Acta Endocrinol. Suppl. 205, 185–198 (1976).
  CAS Google Scholar
• Milner, R. D. G. & Fiodh, H. (eds) Immunological Aspects of Human Growth Hormone: Proceedings of a Workshop, London, 12 November 1985. (Medical Education Services, Oxford, 1986).These papers give a comprehensive review of the immunogenicity of pituitary-derived and early-recombinant-DNA-derived human growth hormones.
  Google Scholar
• Jacquemin, M. G. & Saint-Remy, J. M. Factor VIII immunogenicity. Haemophilia 4, 552–557 (1998).
  Article CAS PubMed Google Scholar
• Dietrich, F. M., Fischer, J. A. & Bijvoet, O. L. Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease. Acta Endocrinol. 92, 468–476 (1979).
  Article CAS PubMed Google Scholar
• Schernthaner, G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16, 155–165 (1993).
  Article PubMed Google Scholar
• Rosenschein, U., Lenz, R., Radnay, J., Ben Tovim, T. & Rozenszajn, L. A. Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction. Isr. J. Med. Sci. 27, 541–545 (1991).
  CAS PubMed Google Scholar
• Vanderschueren, S. M., Stassen, J. M. & Collen, D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb. Haemost. 72, 297–301 (1994).
  Article CAS PubMed Google Scholar
• Chaffee, S. et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Invest. 89, 1643–1651 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Grauer, A., Frank-Raue, K., Schroth, J., Raue, F. & Ziegler, R. Neutralizing antibodies against salmon calcitonin. The cause of a treatment failure in Paget's disease. Dtsch. Med. Wochenschr. 119, 507–510 (1994).
  Article CAS PubMed Google Scholar
• Gilles, J. G., Jacquemin, M. G. & Saint-Remy, J. M. Factor VIII inhibitors. Thromb. Haemost. 78, 641–646 (1997).
  Article CAS PubMed Google Scholar
• Frasier, S. D. Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr. Rev. 4, 155–170 (1983).
  Article CAS PubMed Google Scholar
• Dummer, R. et al. Formation of neutralizing antibodies against natural interferon-β, but not against recombinant interferon-γ during adjuvant therapy for high-risk malignant melanoma patients. Cancer 67, 2300–2304 (1991).
  Article CAS PubMed Google Scholar
• Prabhakar, S. S. & Muhlfelder, T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin. Nephrology 47, 331–335 (1997).
  CAS Google Scholar
• Oberg, K. et al. Treatment of malignant carcinoid tumors with recombinant interferon-α2B: development of neutralizing interferon antibodies and possible loss of antitumor activity. J. Natl Cancer Inst. 81, 531–535 (1989).One of the first studies to show the inhibition of efficacy by antibodies that are induced by human IFN-α.
  Article CAS PubMed Google Scholar
• Zang, Y. C. et al. Immunoregulation and blocking antibodies induced by interferon-β treatment in MS. Neurology 55, 397–404 (2000).
  Article CAS PubMed Google Scholar
• Kontsek, P., Liptakova, H. & Kontsekova, E. Immunogenicity of interferon-α2 in therapy: structural and physiological aspects. Acta Virol. 43, 63–70 (1999).
  CAS PubMed Google Scholar
• Melian, E. B. & Plosker, G. L. Interferon αcon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 61, 1661–1691 (2001).
  Article CAS PubMed Google Scholar
• Girard, F. & Gourmelen, M. Clinical experience with somatonorm. Acta Pœdiatr. Scand. 325, 29–32 (1986).
  Article CAS Google Scholar
• Gribben, J. G. et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335, 434–437 (1990).
  Article CAS Google Scholar
• Karpusas, M. et al. The structure of human interferon-β: implications for activity. Cell. Mol. Life Sci. 54, 1203–1216 (1998).
  Article CAS PubMed Google Scholar
• MacDougall, I. C. Novel erythropoiesis stimulating protein. Semin. Nephrology 20, 375–381 (2000).
  CAS Google Scholar
• Antonelli, G. et al. Interferon antibodies in patients with infectious diseases. Biotherapy 10, 7–14 (1997).
  Article CAS PubMed Google Scholar
• Prümmer, O. Treatment-induced antibodies to interleukin-2. Biotherapy 10, 15–24 (1997).
  Article PubMed Google Scholar
• Stubbe, P. in Growth Hormone Deficiency. Proceedings of a Workshop in Tubingen, 1981 (eds Ranke, M. B. & Bierich, J. R.) 92–99 (Urban and Schwarzenberg, Munich, 1983).
  Google Scholar
• Fierlbeck, G. et al. Neutralizing interferon-β antibodies in melanoma patients treated with recombinant and natural interferon-β. Cancer Immunol. Immunother. 39, 263–268 (1994).
  Article CAS PubMed Google Scholar
• Hochuli, E. Interferon immunogenicity: technical evaluation of interferon-α2A. J. Int. Cytokine Res. 17, S15–S21 (1997).The first study to link the immunogenicity of human IFN-α2A to the presence of oxidized proteins.
  CAS Google Scholar
• Moore, W. V. & Leppert, P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 51, 691–697 (1980).
  Article CAS PubMed Google Scholar
• Ryff, J.-C. Clinical investigation of the immunogenicity of interferon-α2A. J. Int. Cytokine Res. 17, S29–S33 (1997).
  CAS Google Scholar
• Rosendaal, F. R. et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 81, 2180–2186 (1993).This study shows the induction of immunogenicity by the introduction of a pasteurization step during production.
  CAS PubMed Google Scholar
• Cleland, J. L., Powell, M. F. & Shire, S. J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10, 307–377 (1993).
  CAS PubMed Google Scholar
• Palleroni, A. V. et al. Interferon immunogenicity: preclinical evaluation of interferon-α2A. J. Int. Cytokine Res. 17, S23–S27 (1997).
  CAS Google Scholar
• Perini, P. et al. Interferon-β (IFN-β) antibodies in interferon-β1A- and interferon-β1B-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo. Eur. Cytokine Netw. 12, 56–61 (2001).
  CAS PubMed Google Scholar
• Kirchner, H. et al. Subcutaneous interleukin-2 and interferon-α2B in patients with metastatic renal cell cancer: the German outpatient experience. Mol. Biother. 2, 145–154 (1990).
  CAS PubMed Google Scholar
• Levy, F., Muff, R., Dotti-Sigrist, S., Dambacher, M. A. & Fischer, J. A. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J. Clin. Endocrinol. Metab. 67, 541–545 (1988).
  Article CAS PubMed Google Scholar
• Eisenberg, J. D. et al. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J. Pediatr. 131, 118–124 (1997).
  Article CAS PubMed Google Scholar
• Ross, C. et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol. 48, 706–712 (2000).
  Article CAS PubMed Google Scholar
• Antonelli, G. In vivo development of antibodies to interferon: an update to 1996. J. Int. Cytokine Res. 17, S39–S46 (1997).
  CAS Google Scholar
• Prescott, R. et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood 89, 3663–3671 (1997).
  CAS PubMed Google Scholar
• Fakharzadeh, S. S. & Kazazian, H. H. Jr. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin. Thromb. Hemost. 26, 167–171 (2000).
  Article CAS PubMed Google Scholar
• Schernthaner, G. et al. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. Diabetes Care 6, 43–48 (1983).
  PubMed Google Scholar
• Jeandidier, N. et al. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 38, 577–584 (1995).
  Article CAS PubMed Google Scholar
• Schellekens, H., Ryff, J.-C. & van der Meide, P. H. Assays for antibodies to human interferon-α: the need for standardisation. J. Int. Cytokine Res. 17, 5–8 (1997).
  Google Scholar
• Casadevall, N. et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469–475 (2002).An excellent clinical study, which shows the severe clinical consequences of the immunogenicity of a protein drug.
  Article CAS PubMed Google Scholar
• Wang, B. S. et al. Augmentation of hormonal activities with antibodies from cattle immunized with a combination of synthetic and recombinant growth hormone peptide. Anim. Biotechnol. 9, 21–33 (1998).
  Article CAS PubMed Google Scholar
• Zipkin, I. Amgen lays MGDF to rest. BioCentury [online] (cited 29 Apr 02) 〈http://www.biocentury.com/〉 (1998).
• Chan, S. H. et al. Engineering of a mini-trichosanthin that has lower antigenicity by deleting its C-terminal amino acid residues. Biochem. Biophys. Res. Commun. 270, 279–285 (2000).
  Article CAS PubMed Google Scholar
• Collen, D. et al. Recombinant staphylokinase variants with altered immunoreactivity. I. Construction and characterization. Circulation 94, 197–206 (1996).
  Article CAS PubMed Google Scholar
• Chang, T. Y. Towards a quantitative model of immunogenicity: counting pathways in sequence space. J. Theor. Biol. 206, 255–278 (2000).
  Article CAS PubMed Google Scholar
• Van Regenmortel, M. H. Analysing structure–function relationships with biosensors. Cell. Mol. Life Sci. 58, 794–800 (2001).
  Article CAS PubMed Google Scholar
• Vanderschueren, S. M., Stassen, J. M. & Collen, D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb. Haemost. 72, 297–301 (1994).
  Article CAS PubMed Google Scholar
• Collen, D., De Cock, F. & Stassen, J. M. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 87, 996–1006 (1993).
  Article CAS PubMed Google Scholar
• Dempster, A. M. Nonclinical safety evaluation of biotechnologically derived pharmaceuticals. Biotechnol. Annu. Rev. 5, 221–258 (2000).
  Article CAS PubMed Google Scholar
• Randolph, J. F., Stokol, T., Scarlett, J. M. & MacLeod, J. N. Comparison of biological activity and safety of recombinant canine erythropoietin with that of recombinant human erythropoietin in clinically normal dogs. Am. J. Vet. Res. 60, 636–642 (1999).
  CAS PubMed Google Scholar
• Zwickl, C. M. et al. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fundam. Appl. Toxicol. 16, 275–287 (1991).
  Article CAS PubMed Google Scholar
• Wierda, D., Smith, H. W. & Zwickl, C. M. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 158, 71–74 (2001).
  Article CAS PubMed Google Scholar
• Ottesen, J. L. et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37, 1178–1185 (1994).
  Article CAS PubMed Google Scholar
• Stewart, T. A. et al. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol. Biol. Med. 6, 275–281 (1989).The first study to show the relevance of immunotolerant transgenic mice for predicting the immunogenicity of proteins in man.
  CAS PubMed Google Scholar
• Palleroni, A. V. et al. Interferon immunogenicity: preclinical evaluation of interferon-α2A. J. Int. Cytokine Res. 17, S23–S27 (1997).
  CAS Google Scholar
• Du, X. & Tang, J. G. Effects of deleting A19 tyrosine from insulin. Biochem. Mol. Biol. Int. 44, 507–513 (1998).
  CAS PubMed Google Scholar
• Steis, R. G. et al. Loss of interferon antibodies during prolonged continuous interferon-α2A therapy in hairy cell leukemia. Blood 77, 792–798 (1991).
  CAS PubMed Google Scholar
• Roffi, L. et al. Breakthrough during recombinant interferon-α therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 21, 645–649 (1995).
  Article CAS PubMed Google Scholar
• Schellekens, H. & Ryff, J.-C. Biogenerics; the Off-Patent Biotech Products. Trends Pharmacol. Sci. 23, 119–121 (2002).
  Article CAS PubMed Google Scholar
• Chaffee, S. et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Invest. 89, 1643–1651 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Blumenfeld, Z., Frisch, L. & Conn, P. M. Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH-diagnosis and possible alternative treatment. Fertil. Steril. 50, 622–629 (1988).
  Article CAS PubMed Google Scholar
• Olsen, E. et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376–388 (2001).
  Article CAS Google Scholar
• Claustrat, B., David, L., Faure, A. & Francois, R. Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients. J. Clin. Endocrinol. Metab. 57, 1041–1047 (1983).
  Article CAS PubMed Google Scholar
• Ragnhammar, P. & Wadhwa, M. Neutralising antibodies to granulocyte-macrophage colony stimulating factor(GM–CSF) in carcinoma patients following GM-CSF combination therapy. Med. Oncol. 13, 161–166 (1996).
  Article CAS PubMed Google Scholar